We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01003405
First Posted: October 28, 2009
Last Update Posted: July 27, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Kissei Pharmaceutical Co., Ltd.
October 27, 2009
October 28, 2009
July 27, 2010
Not Provided
Not Provided
The long-term safety of KUC-7483 for the treatment of overactive bladder. [ Time Frame: 52 weeks ]
Same as current
Complete list of historical versions of study NCT01003405 on ClinicalTrials.gov Archive Site
The long-term efficacy of KUC-7483 for the treatment of overactive bladder. [ Time Frame: 52 weeks ]
Same as current
Not Provided
Not Provided
 
Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder
To investigate the long-term safety, efficacy and pharmacokinetics of KUC-7483 in patients with overactive bladder.
Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Overactive Bladder
Drug: KUC-7483
Experimental: KUC-7483
Intervention: Drug: KUC-7483
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
100
Not Provided
Not Provided

Inclusion Criteria:

  • Patients who have successfully completed the Phase III double-blind study.

Exclusion Criteria:

  • Patients with serious adverse events or clinically significant adverse events in the Phase III double-blind study.
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01003405
KUC1302
No
Not Provided
Not Provided
Not Provided
Kissei Pharmaceutical Co., Ltd.
Not Provided
Study Director: Yasuhiro Omori Clinical Development Department, Kissei pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP